A research project led by the Ineos Oxford Institute for antimicrobial research (IOI) to study the cause and impact of ...

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

A team of Toronto researchers has received Health Canada approval to conduct clinical trials for a novel class of ...

Answer ALS, a large-scale research initiative headquartered in New Orleans and Washington, D.C., has announced the launch of ...

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...

The ongoing Phase I/IIa study (NCT04725331) is a multicenter, open label, dose-escalation study evaluating BT-001 as a single agent and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) ...

Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

Chief Executive Miranda Toledano said Entera's agreement with the FDA allows Enterea to advance its clinical-development program without having to wait for FDA's qualification of the Study to Advance ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favora ...